Physician profile
Steven Jon Russell
NPI 1679554042
$444,705.70
in general payments reported to CMS, 2019-2025
12 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $370K · 2021: $17K · 2022: $1,455 · 2023: $348 · 2024: $15K · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $16K · Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $15,563.56 |
| Food and Beverage | $681.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $348,151.70 | 2020 | |
| Novo Nordisk As | $34,880.73 | 2019-2020 | |
| Medtronic, INC. | $30,630.64 | 2021-2025 | Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $22,944.83 | 2019 | |
| Convatec INC. | $5,120.00 | 2019-2022 | |
| Lilly USA, LLC | $1,837.50 | 2020 | |
| Dexcom, INC. | $308.26 | 2023-2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $283.36 | 2023 | Ilet Bionic Pancreas |
| Senseonics, Incorporated | $240.00 | 2021 | |
| Mannkind Corporation | $118.80 | 2022 | |
| Zealand Pharma A/S | $100.00 | 2020 | |
| Abbott Laboratories | $89.88 | 2025 | Freestyle Libre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.